米非司酮、达那唑在重度盆腔子宫内膜异位症术后的临床应用  

Clinical Application of Mifepristone and Danazol Treatment for Postoperative Patients with Severepelvic Endometriosis

作　　者：林淑莉 

机构地区：[1]蒙阴县人民医院妇产科,山东蒙阴276200

出　　处：《中国伤残医学》2008年第3期24-25,共2页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探讨米非司酮及达那唑用于盆腔子宫内膜异位症(以下简称内异症)术后辅助治疗的疗效及安全性。方法:回顾分析了136例盆腔内异症患者术后随访资料,比较术后应用米非司酮、达那唑及未用药组的复发率及药物副反应。结果:米非司酮组、达那唑组复发率分别为3.92%、10.53%,低于未用药组34.04%(P<0.05,P<0.05)。米非司酮组肝功损害发生率3.92%显著低于达那唑组39.47%。结论:米非司酮、达那唑用于盆腔内异症的术后辅助治疗是有效的,米非司酮副反应较少。Objective： To investigate the effects and safety of mifepristone and danazol for treating postoperative patients with severe pelvic endometriosis.Methods： 136 severe pelvic endometriosis cases were analyzed retrospectively. Recurrence rate and side effect rate were compared among these groups. Results： The recurrence rate of mifepristone group and danazol group was 3. 92% and 10. 53%, respectively, which was significantly lower than that of control group （p〈0. 05）. The side effect rate of mife-pristone group was 3.92%, which was significantly lower than of danazol group 39.47%. Conclusion： The treatment of mifepristone and danazol on postoperative patients with pelvic endometriosis is effective, mifepristone has less side effects than that of danazol.

关 键 词：米非司酮 迭那唑 子宫内膜异位症 

分 类 号：R711.32[医药卫生—妇产科学]